Human Genome Sciences

ROCKVILLE, Maryland and LONDON - - BENLYSTA (belimumab) met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo in BLISS-52 - - First drug for lupus to reach this advanced stage of clinical development and achieve positive results, in the largest randomized placebo-controlled clinical trial ever completed in SLE patients - Human Genome Sciences, Inc.